Greater China Digest: Moongate, MITRO Biotech, New Radiomedicine snap up funding

Greater China Digest: Moongate, MITRO Biotech, New Radiomedicine snap up funding

Image from Unsplash.

Hong Kong crypto VC firm CMCC Global has led the seed funding round of Moongate while MITRO Biotech and New Radiomedicine Technology have bagged fresh funding.

CMCC Global leads Moongate’s $2.7m seed round

Moongate, which provides non-fungible token (NFT) ticketing and membership solutions for brands and event organisers, has sealed its $2.7-million seed round led by CMCC Global’s Titan Fund. 

The round saw the participation of Token Bay Capital, Penrose Ventures, RNR Capital, Cogitent Ventures, GBV Capital, PHD Capital, as well as notable angel investors from Coingecko, Synthetix, and Dolphin Browser, according to a release on Tuesday. 

The firm also bagged ecosystem grants and support from Arbitrum, Polygon, Avalanche, and BNB Chain. 

Founded in 2022, Moongate’s ticketing solutions have been adopted in major events including Wonderfruit, one of Southeast Asia’s largest music festivals; and ComplexCon, a globally renowned cultural event.

CMG-SDIC Capital leads MITRO Biotech’s $55.3m round 

MITRO Biotech, which offers outsourcing contract research for drug development leveraging radiolabeling and molecular imaging techniques, has raised 400 million yuan ($55.3 million) in an equity financing round. 

Led by CMG-SDIC Capital, the round saw the participation of state-affiliated investors including SDIC JULI Investment Management and Shandong Industry Fund, according to a release on March 18. 

Founded in 2012, the Nanjing-registered firm is a subsidiary of Shenzhen-listed pharmaceutical group Yantai Dongcheng. 

Sichuan Venture Capital invests in New Radiomedicine Technology 

Chengdu New Radiomedicine Technology, which is engaged in the R&D of radiopharmaceuticals, has snagged 300 million yuan ($41.7 million) in a Series C round, according to a release on March 14. 

A slew of Chengdu-based investors have injected capital into the firm including Chengdu Science and Technology Innovation Investment Group; Chengdu Biological City Equity Investment; and Sichuan Venture Capital.

Huaxing Kangping Healthcare Private Fund Management, Neovision Capital, and Star Capital also joined the round. 

Edited by: Padma Priya

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter

This is your last free story for the month. Register to continue reading our content